Literature DB >> 2223422

A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.

E Hardy1, S Kumar, S Peaker, M Feely, T Pullar.   

Abstract

1. Although, long half-life compounds appear to be more appropriate pharmacological indicators of compliance with treatment, short half-life markers or measurements of short half-life therapeutic drugs are frequently used. 2. We have compared the usefulness of low-dose phenobarbitone (a long half-life indicator), low dose isoniazid (a short half-life marker) and controlled release metoprolol (Metros) (a controlled release formulation of a short half-life 'therapeutic' drug) in seven volunteers with simulated partial (two thirds) compliance. 3. Detection of isoniazid metabolites in urine had an 83% sensitivity and 94% specificity for detecting ingestion within the previous 24 h and 100% sensitivity and 82% specificity for detecting ingestion within the past 6 h but gave no indication of the longer term pattern of compliance. 4. At 28 days (a time when steady-state would be obtained for all three drugs) phenobarbitone plasma levels were 70% (66-76%)--median and interquartile range--of the expected steady-state level if compliance had been complete. Corresponding figures for metoprolol were 82% (37-100%). 5. Measurement of phenobarbitone was much superior to isoniazid or metoprolol measurements in reflecting partial compliance over the previous 1 to 4 weeks.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223422      PMCID: PMC1368147          DOI: 10.1111/j.1365-2125.1990.tb03795.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Measurement of low (sub-therapeutic) phenobarbitone levels in plasma by high-performance liquid chromatography: application to patient compliance studies.

Authors:  S Peaker; A C Mehta; S Kumar; M Feely
Journal:  J Chromatogr       Date:  1989-12-29

2.  A sensitive urine-test method for monitoring the ingestion of isoniazid.

Authors:  G A Ellard
Journal:  J Clin Pathol       Date:  1977-01       Impact factor: 3.411

3.  General concepts for use of markers in clinical trials.

Authors:  L Gordis
Journal:  Control Clin Trials       Date:  1984-12

Review 4.  Understanding and improving patient compliance.

Authors:  S A Eraker; J P Kirscht; M H Becker
Journal:  Ann Intern Med       Date:  1984-02       Impact factor: 25.391

5.  Who is taking their tablets?

Authors:  R M Pearson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-18

6.  An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs.

Authors:  G A Ellard; P J Jenner; P A Downs
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

7.  Oros controlled-release formulations of metoprolol: an approach to the development of a system for once daily administration.

Authors:  W Good; L J Leeson; S L Zak; W E Wagner; J B Meeker; J D Arnold
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction.

Authors:  D E Price; A Mehta; B K Park; A Hay; M P Feely
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

9.  Drug defaulting in a general practice.

Authors:  A M Porter
Journal:  Br Med J       Date:  1969-01-25

10.  Statement of the problem and pharmacological and clinical requirements for the ideal marker.

Authors:  W Insull
Journal:  Control Clin Trials       Date:  1984-12
View more
  5 in total

1.  Patient compliance.

Authors:  S Allard
Journal:  BMJ       Date:  1992-12-05

Review 2.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Compliance with drug therapy.

Authors:  T Pullar
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 4.  Once a day is best: evidence or assumption? The relationship between compliance and dosage frequency in older people.

Authors:  M Pushpangadan; M Feely
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

5.  Initial evaluation of low-dose phenobarbital as an indicator of compliance with antimalarial drug treatment.

Authors:  J Karbwang; W Fungladda; C E Pickard; S Shires; A Hay; M Feely
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.